Studies have shown that LGALS9 is cytotoxic to leukemic stem cells derived from patients with ALL, and that the protein encoded by this gene does not show killing activity against normal stem cells of the organism, suggesting an important role of its high expression for the targeted treatment of ALL [53, 54]. This evidence concerns the gene LGALS9 and acute lymphoblastic leukemia.